Company
Herantis Pharma
- Biotech
- Location:
- Espoo, Finland
Description
Herantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug development to unmet clinical needs in conditions where progression remains inadequately addressed.
Herantis Pharma is located in the Helsinki ecosystem.
Related
BraineverBrainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing…
Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
Anacalypsis TherapeuticsAnacalypsis Therapeutics creates precision gene- and pathway-based therapeutic strategies, biomarkers, and genetically linked targets to…
Captor TherapeuticsCaptor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and…
BioArcticBioArctic develops therapeutics and related technologies for neurodegenerative disorders, focusing on disease-modifying treatments and…
HealxHealx builds AI-driven drug discovery and development tools and therapies for rare disease patients, applying AI across discovery,…
- AplagonAplagon develops a therapeutic called APAC, a vascular-injury targeting molecule that combines antiplatelet, anticoagulant, and…
ResQ BiotechResQ Biotech builds a living-cell discovery platform that biosynthesizes and functionally screens ultra-large libraries to identify…
BiohitBiohit develops diagnostic products and services for medical research and early detection, producing assays, clinical study protocols and…